Leslie W. Kreis

Filings by Leslie W. Kreis span 5 companies, the busiest being Lantern Pharma Inc., In8bio, Inc. and Cognition Therapeutics Inc. We count 55 filings; the first trade dates from 3 August 2021 and the latest from 27 June 2025.

Market trades split into 18 purchases (€1.4M) and 28 sales (€826k). The totals do not cover 1 filing with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 7 share grants. So far in 2025, the count stands at 1 purchase and 17 sales.

The median purchase comes to €14k. Clusters matter here: 18 out of 18 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 17 purchases show a median change of -42.5%, with the price up in 18% of them. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 30 June 2025 with an open-market purchase (€428k) in Actuate Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.